TheraRadar
← Back
Data updated: Jun 28, 2026

Apotex

Generics

Apotex is a generic drug manufacturer focused on Cardiovascular, Neurology, Oncology. Key products include IVRA.

1964
Since
276
Drugs
-
Trials
5
New Drugs (2yr)
Modality:
4 Small Molecules

Apotex's Recent FDA Approvals

Apotex secured 5 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

EVDI NDA
2026-05-01
trabectedin
1 INDICATIONS AND USAGE EVDI is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . EVDI is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )
DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
BENDAMUSTINE HYDROCHLORIDE NDA
2025-07-03
bendamustine hydrochloride
BORTEZOMIB NDA
2024-08-26
bortezomib
1 INDICATIONS AND USAGE Bortezomib for injection is a proteasome inhibitor indicated for: • treatment of adult patients with multiple myeloma ( 1.1 ) • treatment of adult patients with mantle cell lymphoma ( 1.2 ) 1.1 Multiple Myeloma Bortezomib for injection is indicated for the treatment of adult patients with multiple myeloma. 1.2 Mantle Cell Lymphoma Bortezomib for injection is indicated for the treatment of adult patients with mantle cell lymphoma.

Apotex's Therapeutic Areas

Apotex's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 31%
22 drugs
Neurology 24%
17 drugs
Oncology 17%
12 drugs
Infectious Disease 17%
12 drugs
Dermatology 10%
7 drugs

Apotex Pipeline Snapshot

Active clinical trials for Apotex across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM leads revenue
  • 5 key drugs tracked

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling